Roche's pricey new hemophilia drug Hemlibra gets a rare blessing from U.S. cost watchdogs
admin 30th January 2018 Uncategorised 0As the hemophilia market gets increasingly crowded, Roche needs all the help it can get generating enthusiasm for its new entry, Hemlibra. A thumbs-up from the cost watchdogs at the Institute for Clinical and Economic Review (ICER)—who decided Hemlibra is cost-effective, despite its north-of-$400K price—could do just that.
More: Roche's pricey new hemophilia drug Hemlibra gets a rare blessing from U.S. cost watchdogs
Source: fierce